Pfizer, buoyed by a huge jump in sales for its COVID-19 vaccine and solid first-quarter performance across most of the company, hiked its 2021 financial
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
